169 related articles for article (PubMed ID: 27434411)
21. Tyrosine Kinase Inhibition in HPV-related Squamous Cell Carcinoma Reveals Beneficial Expression of cKIT and Src.
Kramer B; Kneissle M; Birk R; Rotter N; Aderhold C
Anticancer Res; 2018 May; 38(5):2723-2731. PubMed ID: 29715092
[TBL] [Abstract][Full Text] [Related]
22. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC).
Zhang F; Li Y; Zhang H; Huang E; Gao L; Luo W; Wei Q; Fan J; Song D; Liao J; Zou Y; Liu F; Liu J; Huang J; Guo D; Ma C; Hu X; Li L; Qu X; Chen L; Yu X; Zhang Z; Wu T; Luu HH; Haydon RC; Song J; He TC; Ji P
Oncotarget; 2017 Feb; 8(8):12968-12982. PubMed ID: 28099902
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
[TBL] [Abstract][Full Text] [Related]
24. IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
Stabile LP; Egloff AM; Gibson MK; Gooding WE; Ohr J; Zhou P; Rothenberger NJ; Wang L; Geiger JL; Flaherty JT; Grandis JR; Bauman JE
Oral Oncol; 2017 Jun; 69():38-45. PubMed ID: 28559019
[TBL] [Abstract][Full Text] [Related]
25. Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma.
Kurth I; Hein L; Mäbert K; Peitzsch C; Koi L; Cojoc M; Kunz-Schughart L; Baumann M; Dubrovska A
Oncotarget; 2015 Oct; 6(33):34494-509. PubMed ID: 26460734
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
27. Anti-cancer activity of a new dihydropyridine derivative, VdiE-2N, in head and neck squamous cell carcinoma.
Goto RN; Sobral LM; Sousa LO; Garcia CB; Lopes NP; Marín-Prida J; Ochoa-Rodríguez E; Verdecia-Reyes Y; Pardo-Andreu GL; Curti C; Leopoldino AM
Eur J Pharmacol; 2018 Jan; 819():198-206. PubMed ID: 29221949
[TBL] [Abstract][Full Text] [Related]
28. cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells.
Miyano K; Cabral H; Miura Y; Matsumoto Y; Mochida Y; Kinoh H; Iwata C; Nagano O; Saya H; Nishiyama N; Kataoka K; Yamasoba T
J Control Release; 2017 Sep; 261():275-286. PubMed ID: 28666729
[TBL] [Abstract][Full Text] [Related]
29. ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy.
Fu G; Somasundaram RT; Jessa F; Srivastava G; MacMillan C; Witterick I; Walfish PG; Ralhan R
Oncotarget; 2016 Mar; 7(13):17162-81. PubMed ID: 26934445
[TBL] [Abstract][Full Text] [Related]
30. Novel C-Terminal Heat Shock Protein 90 Inhibitors (KU711 and Ku757) Are Effective in Targeting Head and Neck Squamous Cell Carcinoma Cancer Stem cells.
Subramanian C; Kovatch KJ; Sim MW; Wang G; Prince ME; Carey TE; Davis R; Blagg BSJ; Cohen MS
Neoplasia; 2017 Dec; 19(12):1003-1011. PubMed ID: 29121598
[TBL] [Abstract][Full Text] [Related]
31. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
[TBL] [Abstract][Full Text] [Related]
32. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
Trials; 2014 Nov; 15():469. PubMed ID: 25432788
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
[TBL] [Abstract][Full Text] [Related]
34. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
35. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
36. Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab.
Luo J; Hong Y; Lu Y; Qiu S; Chaganty BK; Zhang L; Wang X; Li Q; Fan Z
Cancer Lett; 2017 Jan; 384():39-49. PubMed ID: 27693630
[TBL] [Abstract][Full Text] [Related]
37. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
38. Functional analysis of Discoidin domain receptor 2 mutation and expression in squamous cell lung cancer.
Kobayashi-Watanabe N; Sato A; Watanabe T; Abe T; Nakashima C; Sueoka E; Kimura S; Sueoka-Aragane N
Lung Cancer; 2017 Aug; 110():35-41. PubMed ID: 28676216
[TBL] [Abstract][Full Text] [Related]
39. Autophagic action of new targeting agents in head and neck oncology.
Rikiishi H
Cancer Biol Ther; 2012 Sep; 13(11):978-91. PubMed ID: 22825332
[TBL] [Abstract][Full Text] [Related]
40. Blocking of stromal interaction molecule 1 expression influence cell proliferation and promote cell apoptosis in vitro and inhibit tumor growth in vivo in head and neck squamous cell carcinoma.
Li P; Bian XY; Chen Q; Yao XF; Wang XD; Zhang WC; Tao YJ; Jin R; Zhang L
PLoS One; 2017; 12(5):e0177484. PubMed ID: 28494008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]